Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease

PharmacoEconomics

Volumn 11, Issue 1, 1997, Pages 89-110

  Goa, Karen L ^a   Barradell, Lee B ^a   McTavish, Donna ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

COLESTYRAMINE; SIMVASTATIN;

CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; HYPERCHOLESTEROLEMIA; PHARMACOECONOMICS; PRIORITY JOURNAL; REVIEW; SURVIVAL;

EID: 0031034242     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199711010-00010     Document Type: Review

References (112)

1. Chrisp P, Lewis NJW, Milne RJ. Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease. PharmacoEconomics 1992 Feb; 1: 124-45
2. Reckless JPD. The economics of cholesterol lowering. Baillieres Clin Endocrin Metab 1990; 4 (4): 947-72
3. Scott WG, White HD, Scott HM. Cost of coronary heart disease in New Zealand. N Z Med J 1993 Aug 25; 106 (962): 347-9
4. Reckless JPD. Cost-effectiveness of hypolipidaemic drugs. Postgrad Med J 1993; 69 Suppl. 1: S30-3
5. Simvastatin cost-effective in secondary prevention. Scrip 1995 Apr 4; 2013: 30
6. Johannesson M, Borgquist L, Nilsson-Ehle P, et al. The cost of screening for hypercholesterolaemia - results from a clinical trial in Swedish primary health care. Scand J Clin Lab Invest 1993 Nov; 53: 725-32
7. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994 Mar; 89: 1336-445
8. Office of Heath Economics. Coronary heart disease. The need for action. Statement from the Office of Health Economics, London, 1990: 15-18
9. Field K, Thorogood M, Silagy C, et al. Strategies for reducing coronary risk factors in primary care: which is most cost effective? BMJ 1995 Apr 29; 310: 1109-12
10. Ramsay LE, Haq IU, Jackson PR, et al. Targeting lipid-lowering drug therapy for primary prevention of coronary disease; an updated Sheffied table. Lancet 1996 Aug 10; 348: 387-8
11. Kuntz KM, Lee TH. Cost-effectiveness of accepted measures for intervention in coronary heart disease. Coron Artery Dis 1995; 6 (6): 472-8
12. Okayama A, Ueshima H, Marmot MG, et al. Changes in total serum cholesterol and other risk factors for cardiovascular disease in Japan, 1980-1989. Int Epidemiol 1993 Dec; 22: 1038-47
13. Blake GH, Triplett LC. Management of hypercholesterolemia. Am Fam Physician 1995 Apr; 51: 1157-66
14. Tomson Y, Johannesson M, Åberg H. The costs and effects of two different lipid intervention programmes in primary health care. J Intern Med 1995 Jan; 237: 13-7
15. Neaton JD, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med 1992; 152: 1490-500
16. Fletcher AE, Bulpitt CJ. Pharmacoeconomic evaluation of risk factors for cardiovascular disease. An epidemiological perspective. PharmacoEconomics 1992 Jan; 1: 33-44
17. Holme I. Cholesterol reduction and its impact on coronary artery disease and total mortality. Am J Cardiol 1995 Sep 28; 76: 10-7
18. Marchioli R, Marfisi RM, Carinci F, et al. Meta-analysis, clinical trials, and transferability of research results into practice: the case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease. Arch Intern Med 1996 Jun 10; 156: 1158-72
19. O'Brien BJ. Cholesterol and coronary heart disease: consensus or controversy? 8. Questions of cost-effectiveness. London; From the Office of Health Economics 1991: 78-100.
20. Grover SA, Coupal L, Fahkry R, et al. Screening for hypercholesterolemia among Canadians: how much will it cost? Can Med Assoc J 1991; 144 (2): 161-8
21. Lindholm L, Rosén M, Weinehall L, et al. Cost effectiveness and equity of a community based cardiovascular disease prevention programme in Norsjö, Sweden. J Epidemiol Community Health 1996; 50: 190-5
22. Reckless JPD. Cost-effectiveness of clinical care for hyperlipidaemia. In: Lewis B, Assmann G, editors. The social and economic contexts of coronary prevention. London: Current Medical Literature, 1990: 94-104
23. McGehee MM, Johnson EQ, Rasmussen HM, et al. Benefits and costs of medical nutrition therapy by registered dietitians for patients with hypercholesterolemia. J Am Diet Assoc 1995; 95: 1041-3
24. Kinlay S, O'Connell D, Evans D, et al. A new method of estimating cost effectiveness of cholesterol reduction therapy for prevention of heart disease. PharmacoEconomics 1994 Mar; 5: 238-48
25. Davey Smith G, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ 1993 May 22; 306: 1367-73
26. LaRosa JC. Cholesterol lowering, low cholesterol, and mortality. Am J Cardiol 1993 Oct 1; 72: 776-86
27. Wonderling D, McDermott C, Buxton M, et al. Costs and cost effectiveness of cardiovascular screening and intervention: the British family heart study. BMJ 1996; 312: 1269-73
28. Langham S, Thorogood M, Normand C, et al. Costs and cost effectiveness of health checks conducted by nurses in primary care: the Oxcheck study. BMJ 1996 May 18; 312: 1265-8
29. Wonderling D, Langham S, Buxton M, et al. Wha can be concluded from the Oxcheck and British family heart studies: commentary on cost effectiveness analyses. BMJ 1996 May 18; 312: 1274-8
30. Plosker GL, McTavish D, Simvastatin: a reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Drugs 1995 Aug; 50: 334-63
31. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 Nov 19; 344: 1383-9
32. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation 1996 May 15; 95: 1796-802
33. Geurian KL. The cholesterol controversy. Ann Pharmacother 1996; 30: 495-500
34. Hippisley-Cox J. Lowering patients' cholesterol: extrapolating results of trial of Simvastatin gives room for doubt [letter]. BMJ 1995 Sep 9; 311: 690-1
35. Kjekshus J, Pedersen TR, for the Scandinavian Simvastatin Survival Study Group. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995 Sep 28; 76: 64C-8C
36. Tuomilehto J, Guimaraes AC, Kettner H, et al. Dose-response of simvastatin in primary hypercholesterolemia. J Cardiovasc Pharmacol 1994 Dec; 24: 941-9
37. Keech A, Collins R, MacMahon S, et al. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 1994 Feb; 15: 255-69
38. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study Group. Lancet 1995 May 20; 345: 1274-5
39. Lansberg PJ, Mitchel YB, Shapiro D, et al. Long-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patients. Atherosclerosis 1995 Aug; 116: 153-62
40. Quiney J, Watts GF, Kerr-Muir M, et al. One year experience in the treatment of familial hypercholesterolaemia with simvastatin. Postgrad Med J 1992 Jul; 68: 575-80
41. Knops RE, Kroon AA, Mol MJTM, et al. Long-term experience (6 years) with simvastatin in patients with heterozygous familial hypercholesterolaemia. Neth J Med 1995 Apr; 46: 171-8
42. Kazumi T, Yoshino G, Ohki A, et al. Long-term effects of simvastatin in hypercholesterolemic patients with NIDDM and additional atherosclerotic risk factors. Horm Metab Res 1995 May; 27: 239-43
43. Farrer M, Winocour PH, Evans K, et al. Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures. Diabetes Res Clin Pract 1994 Mar; 23: 111-9
44. Miccoli R, Bertolotto A, Giovannitti MG, et al. Simvastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus and in primary hypercholesterolemia. Curr Ther Res 1992 Jan; 51: 66-74
45. Sartor G, Katzman P, Eizyk E, et al. Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus. Int J Clin Pharmacol Ther 1995 Jan; 33: 3-6
46. Martini S, Gabelli C, Pagano GF, et al. Efficacy and safety of simvastatin for the treatment of hypercholesterolemia in patients with and without type II diabetes. Curr Ther Res 1992 Aug; 52: 281-90
47. Nielsen S, Schmitz O, Moller N, et al. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1993 Oct; 36: 1079-86
48. Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 1995 Jul-Aug; 29: 743-59
49. Farmer JA, Washington LC, Jones PH, et al. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. Clin Ther 1992 Sep-Oct; 14: 708-17
50. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther 1994 May-Jun; 16 (3): 366-85
51. Illingworth DR, Bacon S, Pappu AS, et al. Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1992 Sep; 96: 53-64
52. Douste-Blazy P, Ribeiro VG, Seed M, et al. Comparative study of the efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolaemia. Drug Invest 1993 Dec; 6: 353-61
53. Plosker GL, Wagstaff AJ. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. Drugs 1996 Mar; 51 (3): 433-59
54. Malini PL, de Divitiis O, di Somma S, et al. A comparative study of simvastatin versus pravastatin in patients with primary hypercholesterolaemia. Atherosclerosis 1992 Dec; 97 Suppl.: S41-7
55. Lintott CJ, Scott RS, Sutherland WHF, et al. Treating hypercholesterolaemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin. Aust N Z J Med 1993 Aug; 23: 381-6
56. Simvastatin Pravastatin Study Group. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolaemia. Am J Cardiol 1993 Jun 15; 71: 1408-14
57. Boccuzzi SJ, Keegan ME, Hirsch LJ, et al. Long term experience with simvastatin. Drug Invest 1993; 5 (2): 135-40
58. Pedersen TR, Kjekshus J, Pyörälä K, et al. Safety and tolerability of cholesterol-lowering with simvastatin over 5 years in the Scandinavian Simvastatin Survival Study (4S) [abstract]. Presented at the 66th Congress of the European Atherosclerosis Society. Florence, 1996 Jul 13-17; 223
59. Zureik M, Courbon D, Ducimetière P. Serum cholesterol concentration and death from suicide in men: Paris prospective study I. BMJ 1996 Sep 14; 313: 649-51
60. Jungnickel PW. Cholesterol-lowering therapy: is there really a controversy? Ann Pharmacother 1996 May; 30: 539-42
61. Wardle J, Armitage J, Collins R, et al. Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. BMJ 1996 Jul 13; 313: 75-8
62. Drummond MF, Heyse J, Cook J. Selection of end points in economic evaluations of coronary-heart-disease interventions. Med Decis Making 1993 Jul-Sep; 13: 184-90
63. Goldman L, Garber AM, Grover SA, et al. Task force 6. Cost effectiveness of assessment and management of risk factors. J Am Coll Cardiol 1996 Apr; 27: 1020-30
64. Jönsson B, Johannesson M, Kjekshus J, et al. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996; 17: 1001-7
65. Reckless JPD. The 4S study and its pharmacoeconomic implications. PharmacoEconomics 1996 Feb; 9: 101-5
66. Shepherd J, Cobbe SM, Ford J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995; 333: 1301-7
67. Glick H, Heyse JF, Thompson D, et al. A model for evaluating the cost-effectiveness of cholesterol-lowering treatmet. Int J Technol Assess Health Care 1992 Fall; 8: 719-34
68. Martens LL, Rutten FFH, Erkelens DW, et al. Cost effectiveness of cholesterol-lowering therapy in The Netherlands: simvastatin versus cholestyramine. Am J Med 1989; 87 Suppl. 4A: 54S-8S
69. Martens LL, Rutten FFH, Erkelens DW, et al. Clinical benefits and cost-effectivness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in The Netherlands. Am J Cardiol 1990; 65: 27F-32F
70. Hjalte K, Lindgren B, Persson U. Cost-effectiveness of simvastatin versus cholestyramine. Results for Sweden, PharmacoEconomics 1992 Mar; 1: 213-6
71. Martens LL, Guibert R. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Clin Ther 1994 Nov-Dec; 16: 1052-62
72. Martens LL. Cost effectiveness of cholesterol-lowering therapy with simvastatin in the Netherlands [abstract]. Drug Info J 1994 Apr-Jun; 28: 437-8
73. Martens LL, Rutten FFH, Kuijpens JLP, et al. Cost-effectiveness of lowering serum cholesterol levels by simvastatin and cholestyramine [in Dutch]. Ned Tijdschr Geneeskd 1991; 135 (15): 655-9
74. Hamilton VH, Racicot F-E, Zowall H, et al. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: estimating the benefits of increasing HDLC. JAMA 1995 Apr 5; 273: 1032-8
75. Jolain B, Pettitt D. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease [letter]. Clin Ther 1995 May-Jun; 17: 572-5
76. Guibert R. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG CoA reductase inhibitors in the primary prevention of coronary heart disease. Reply [letter]. Clin Ther 1995 May-Jun; 17: 575-80
77. Garnett WR. Fluvastatin cost considerations [letter]. Ann Pharmacother 1994 Sep; 28: 1111-2
78. Lim MCL, Foo WM. Efficacy and cost-effectiveness of simvastatin and gemfibrozil in the treatment of hyperlipidaemia. Ann Acad Med Singapore 1992 Jan; 21: 34-7
79. Smart AJ, Walters L. Pharmaco-economic assessment of the HMG-CoA reductase inhibitors. S Afr Med J 1994 Dec; 84: 834-7
80. Sprecher DL, Jokubaitis L. Cost-effectiveness of combined statin-resin therapy. Reply [letter]. Ann Intern Med 1994 Oct 1; 121: 548-9
81. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994 May 26; 73: 3D-11D
82. Neil HAW, Roe L, Godlee RJP, et al. Randomised trial of lipid lowering dietary advice in general practice: the effects on serum lipids, lipoproteins and antioxidants. BMJ 1996; 310: 569-73
83. Denke MA. Cholesterol-lowering diets. A review of the evidence. Arch Intern Med 1995 Jan 9; 155: 17-26
84. Caggiula AW, Watson JE, Kuller LH, et al. Cholesterol-lowering intervention program: effect of the Step I diet in community office practices. Arch Intern Med 1996 Jun 10; 156: 1205-13
85. Pyörälä K, De Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 1994; 110: 121-61
86. Betteridge DJ, Dodson PM, Durrington PN, et al. Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J 1993; 69: 359-69
87. LaRosa JC. Cholesterol agonistics. Ann Intern Med 1996 Mar 1; 124: 505-8
88. New cholesterol screening guidelines 'miss the boat'. Pharmacoecon Outcomes News 1996 Mar 16; 53: 2
89. American College of Physicians. Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults. Ann Intern Med 1996; 124: 515-7
90. Garber AM, Browner WS, Hulley SB. Cholesterol screening in asymptomatic adults, revisited. Ann Intern Med 1996 Mar 1; 124: 518-31
91. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993 Jun 16; 269: 3015-23
92. ACP cholesterol screening guidelines are 'likely to confuse'. FDC Rep Pink Sheet 1996 Mar 4; T&G 12
93. FDA approves Zocor label change. Marketletter 1995 (10 Jul); 23
94. Additional simvastatin indications. Inpharma 1995 Oct 14; 1008: 22 95. Canada's Health Protection Branch has approved Merck Frosst Canada's Zocor. Marketletter 1996 May 20; 23: 28
95. Lipid-lowering agents: where is the evidence of increased survival? WHO Drug Info 1994; 8 (4): 204-6
96. Yusuf S. Anand S. Cost of prevention. The case of lipid lowering. Circulation 1996; 93: 1774-6
97. Aursnes I, Thorvik E, Forsén L, et al. Evaluation of the cost-effectiveness ratio of cholesterol-lowering drugs in secondary prevention of myocardial infarction [abstract]. The 3rd International Symposium on Multiple Risk Factors in Cardiovascular Disease Vascular and Organ Protection: 1994 Jul 6-9; Florence, 26.
98. Goldman L et al. Cost-effectiveness of HMG-CoA reduclase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991; 265 (9): 1145-51
99. Ashraf T, Hay JW, Crouse JR, et al. The cost-effectiveness of pravastatin in secondary prevention of coronary heart disease. Am J Cardiol 1995; 78: 409-14
100. Sacks FM, Pfeffer MA, Move LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996 Oct 3; 335 (14): 1001-9
101. LaRosa JC. Cholesterol-lowering and the cost-effective prevention of recurrent coronary disease. CVR&R 1996 Aug: 10-28
102. ASPIRE Steering Group. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease. ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Principal results. Heart 1996; 75: 334-42
103. Zocor gains life-saving indication in US. Scrip 1995 Jul 14; 2042: 16
104. Shepherd J. Pratt M. Prevention of coronary heart disease in clnical practice: a commentary on current treatment patterns in six European countries in relation to published recommendations. Cardiology 1996; 87: 1-5
105. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996; 100: 605-10
106. Jackson R, Beaglehole R. Evidence-based management of dyslipidaemia. Lancet 1995 Dec 2; 346: 1440-2
107. Dyslipidaemia Advisory Group, on behalf of the National Heart Foundation of New Zealand. 1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. N Z Med J 1996; 109: 224-32
108. Kaplan NM. Lipid intervention trials in primary prevention: a critical review. Clin Exp Hypertens 1992; A14 (1&2): 109-18
109. Pharoah PDP, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 1996 Jun 8; 312: 1443-8
110. Haq IU, Jackson PR, Yeo WW, et al. Lipid-lowering for primary prevention of coronary disease: what policy now? [abstract]. The 66th Congress of the European Atherosclerosis Society: 1996, Jul 13-17; Florence, 103.
111. Malik IS, Anderson MH. Cost-efficacy of cholesterol lowering: West of Scotland Coronary Prevention Study versus the Scandinavian Simvastatin Survival Study [abstract]. Heart 1996 May; 75 Suppl. 1: 77
112. Hyperlipidaemia: new evidence about treatment. MeReC Bull 1996 April; 7 (4): 13-6